Washington State Senator John Braun’s Campaign Financing and Voting Record
John Braun, a state senator from Washington, has seen significant financial backing from the pharmaceutical and health insurance sectors during his time in politics. These contributions have sparked discussions due to his voting record on health care legislation.
Currently, Braun is campaigning for a position in the U.S. House representing Washington’s 3rd District, a seat presently held by Democrat Marie Gluesenkamp Perez.
According to campaign finance data, Braun has received $73,550 from pharmaceutical companies and $37,400 from health insurance interests since 2012. Contributions from these industries account for about 10% of his total donations.
In 2022, Braun opposed a bipartisan initiative to create Washington’s Prescription Drug Affordability Board. This board is tasked with evaluating medication costs and potentially setting price caps for consumers, state entities, and insurers.
The AARP highlighted that the board “could lead to lower insurance premiums, reduce taxpayer spending on health care, and would help ensure people can afford the medication they need.” However, PhRMA, a pharmaceutical trade association that contributed to Braun’s campaign in 2015 and 2016, has criticized such affordability boards.
In a previous instance, Braun opposed legislation that would allow Washington to procure, produce, and distribute generic drugs as cheaper alternatives to brand-name medications. This occurred the year prior to the affordability board vote.
Additionally, Braun voted against a 2020 bill aimed at bulk purchasing insulin to offer it at reduced rates and another bill mandating health insurers to cover pre-existing conditions.
Despite these actions, Braun claims that reducing costs remains a central focus of his political agenda. In June, he took issue with Gluesenkamp Perez for opposing a major tax reduction, which he described as “the largest tax cut in history,” but the measure has been criticized for favoring the wealthy and reducing Medicaid funding by $1 trillion.
Health care affordability is anticipated to be a pivotal topic in the 2026 election. A June 2026 Gallup poll indicated that the public’s ability to afford health care has diminished to its lowest point in five years.
Furthermore, Braun’s bid for the House has received the endorsement of former President Donald Trump.
The post Braun took drug industry money, opposed lower health care costs appeared first on American Journal News.
—
Read More Kitchen Table News
